RU2020108634A - Аналоги карбамоилфенилаланинола и способы их применения - Google Patents
Аналоги карбамоилфенилаланинола и способы их применения Download PDFInfo
- Publication number
- RU2020108634A RU2020108634A RU2020108634A RU2020108634A RU2020108634A RU 2020108634 A RU2020108634 A RU 2020108634A RU 2020108634 A RU2020108634 A RU 2020108634A RU 2020108634 A RU2020108634 A RU 2020108634A RU 2020108634 A RU2020108634 A RU 2020108634A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- compound
- pharmaceutically acceptable
- compound according
- acceptable salt
- Prior art date
Links
- NJVZDURTFWBXAM-VIFPVBQESA-N [(2S)-1-hydroxy-3-phenylpropan-2-yl]urea Chemical class C(N)(=O)N[C@@H](CC1=CC=CC=C1)CO NJVZDURTFWBXAM-VIFPVBQESA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 206010041349 Somnolence Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 3
- 208000016588 Idiopathic hypersomnia Diseases 0.000 claims 3
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 208000001573 Cataplexy Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000025748 atypical depressive disease Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- -1 cyano, hydroxy Chemical group 0.000 claims 2
- 150000001923 cyclic compounds Chemical class 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 201000003631 narcolepsy Diseases 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000005309 thioalkoxy group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000032140 Sleepiness Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000014679 binge eating disease Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 229940126214 compound 3 Drugs 0.000 claims 1
- 229940125898 compound 5 Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 230000037321 sleepiness Effects 0.000 claims 1
- 230000005586 smoking cessation Effects 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/02—Monothiocarbamic acids; Derivatives thereof
- C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539088P | 2017-07-31 | 2017-07-31 | |
| US62/539,088 | 2017-07-31 | ||
| PCT/US2018/044465 WO2019027941A1 (en) | 2017-07-31 | 2018-07-31 | CARBAMOYL PHENYLALANINOL ANALOGUES AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020108634A true RU2020108634A (ru) | 2021-09-02 |
| RU2020108634A3 RU2020108634A3 (enExample) | 2021-11-30 |
Family
ID=65233074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020108634A RU2020108634A (ru) | 2017-07-31 | 2018-07-31 | Аналоги карбамоилфенилаланинола и способы их применения |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11413264B2 (enExample) |
| EP (1) | EP3661911A4 (enExample) |
| JP (2) | JP7366002B2 (enExample) |
| KR (1) | KR102643275B1 (enExample) |
| CN (1) | CN111094238B (enExample) |
| AU (1) | AU2018312328B2 (enExample) |
| CA (1) | CA3071779A1 (enExample) |
| MX (2) | MX2020001146A (enExample) |
| RU (1) | RU2020108634A (enExample) |
| SA (1) | SA520411187B1 (enExample) |
| SG (1) | SG11202000817SA (enExample) |
| WO (1) | WO2019027941A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| RU2020108634A (ru) * | 2017-07-31 | 2021-09-02 | Джаз Фармасьютикалз Айрлэнд Лимитед | Аналоги карбамоилфенилаланинола и способы их применения |
| AU2020231916B2 (en) | 2019-03-01 | 2025-08-28 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| EP4531833A2 (en) * | 2022-06-03 | 2025-04-09 | Axsome Therapeutics | Carbamoyl phenylalaninol compounds as taar1 agonists |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2604434B1 (fr) * | 1986-09-29 | 1989-05-19 | Inst Nat Sante Rech Med | Derives d'amino-2 ethanethiol, leur preparation et leur application en therapeutique |
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| CA2240060C (en) * | 1996-10-10 | 2007-07-17 | Sk Corporation | O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same |
| AU4674797A (en) * | 1996-10-22 | 1998-05-15 | Ortho Pharmaceutical Corporation | Phenylalaninol derivatives for the treatment of central nervous system disorders |
| US5935997A (en) * | 1998-01-13 | 1999-08-10 | Yukong Limited | O-thiocarbamoyl-aminoalkanol compounds, their pharmaceutically useful salts and process for preparing the same |
| JP4374441B2 (ja) | 1998-12-23 | 2009-12-02 | ジェイピーアイ コマーシャル，リミティド ライアビリティ カンパニー | 睡眠発作治療のための、ガンマ−ヒドロキシ酪酸塩の微生物的に安全で安定な液剤 |
| US7553969B1 (en) * | 1999-01-28 | 2009-06-30 | Chugai Seiyaku Kabushiki Kaisha | Substituted phenethylamine derivatives |
| CN1160329C (zh) * | 1999-02-05 | 2004-08-04 | Sk株式会社 | O-硫代氨基甲酰基-氨基烷醇化合物,其药学上认可的盐及其制备方法 |
| WO2000064865A1 (en) * | 1999-04-23 | 2000-11-02 | Solvay Pharmaceuticals B.V. | Monomers and oligourea peptidomimetics and process for the prepa ration thereof |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| EP1264814A1 (en) * | 2001-06-08 | 2002-12-11 | Avantium International B.V. | Resolving agents based on amines |
| US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
| KR100576372B1 (ko) * | 2001-08-03 | 2006-05-03 | 에스케이 주식회사 | Ｏ-티오카바모일-아미노알카놀 화합물, 이의 약학적 허용염 및 제조방법 |
| ITFI20030113A1 (it) * | 2003-04-24 | 2004-10-25 | Menarini Ricerche Spa | Composti lineari nk-2 antagonisti con caratteristiche basiche e formulazioni che li contengono. |
| WO2006050037A1 (en) | 2004-10-28 | 2006-05-11 | Sk Corporation | Adjunctive therapy for depression |
| PL1890684T3 (pl) * | 2005-06-08 | 2014-05-30 | Sk Biopharmaceuticals Co Ltd | Leczenie zaburzeń snu i czuwania |
| ATE459393T1 (de) | 2005-06-22 | 2010-03-15 | Sk Holdings Co Ltd | Behandlung der sexuellen dysfunktion |
| CN101823987B (zh) * | 2009-03-06 | 2014-06-04 | 中国科学院上海药物研究所 | 一类新的dpp-ⅳ抑制剂及其制备方法和用途 |
| WO2011005473A2 (en) | 2009-06-22 | 2011-01-13 | Shionogi Pharma, Inc. | Methods for treating or preventing fatigue |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| RU2557533C2 (ru) | 2009-11-06 | 2015-07-20 | Ск Биофармасъютиклс Ко., Лтд. | Способы лечения синдрома фибромиалгии |
| ES2447295T3 (es) | 2009-11-06 | 2014-03-11 | Sk Biopharmaceuticals Co., Ltd. | Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| CN102249833B (zh) * | 2011-05-27 | 2013-12-11 | 中国科学院化学研究所 | 一种制备手性γ-氨基酸及其衍生物的方法 |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| BR112015022197B1 (pt) | 2013-03-13 | 2022-06-07 | Sk Biopharmaceuticals Co., Ltd. | Uso de um composto para o tratamento de cataplexia |
| US20150018414A1 (en) | 2013-07-12 | 2015-01-15 | Jazz Pharmaceuticals International lll Limited | Promotion of Smoking Cessation |
| CN105873576B (zh) | 2013-07-18 | 2019-07-19 | 爵士制药国际Iii有限公司 | 治疗肥胖 |
| US10702498B2 (en) * | 2015-07-09 | 2020-07-07 | The Regents Of The University Of California | MU opioid receptor modulators |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| SG11201903076QA (en) | 2016-10-06 | 2019-05-30 | Jazz Pharmaceuticals International Iii Ltd | Carbamoyl phenylalaninol compounds and uses therof |
| RU2020108634A (ru) | 2017-07-31 | 2021-09-02 | Джаз Фармасьютикалз Айрлэнд Лимитед | Аналоги карбамоилфенилаланинола и способы их применения |
-
2018
- 2018-07-31 RU RU2020108634A patent/RU2020108634A/ru unknown
- 2018-07-31 AU AU2018312328A patent/AU2018312328B2/en active Active
- 2018-07-31 EP EP18840981.7A patent/EP3661911A4/en active Pending
- 2018-07-31 SG SG11202000817SA patent/SG11202000817SA/en unknown
- 2018-07-31 WO PCT/US2018/044465 patent/WO2019027941A1/en not_active Ceased
- 2018-07-31 CN CN201880059970.5A patent/CN111094238B/zh active Active
- 2018-07-31 CA CA3071779A patent/CA3071779A1/en active Pending
- 2018-07-31 KR KR1020207005652A patent/KR102643275B1/ko active Active
- 2018-07-31 JP JP2020505344A patent/JP7366002B2/ja active Active
- 2018-07-31 MX MX2020001146A patent/MX2020001146A/es unknown
- 2018-07-31 US US16/634,935 patent/US11413264B2/en active Active
-
2020
- 2020-01-29 MX MX2023005484A patent/MX2023005484A/es unknown
- 2020-01-29 SA SA520411187A patent/SA520411187B1/ar unknown
-
2022
- 2022-06-16 US US17/841,976 patent/US20220401401A1/en not_active Abandoned
-
2023
- 2023-04-26 JP JP2023072520A patent/JP7642707B2/ja active Active
-
2024
- 2024-09-30 US US18/901,040 patent/US20250017890A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210093603A1 (en) | 2021-04-01 |
| CN111094238A (zh) | 2020-05-01 |
| US11413264B2 (en) | 2022-08-16 |
| JP2023100758A (ja) | 2023-07-19 |
| WO2019027941A1 (en) | 2019-02-07 |
| SG11202000817SA (en) | 2020-02-27 |
| US20220401401A1 (en) | 2022-12-22 |
| NZ762140A (en) | 2024-11-29 |
| AU2018312328B2 (en) | 2022-12-15 |
| MX2020001146A (es) | 2020-08-20 |
| EP3661911A4 (en) | 2021-04-14 |
| CA3071779A1 (en) | 2019-02-07 |
| MX2023005484A (es) | 2023-05-18 |
| AU2018312328A1 (en) | 2020-03-19 |
| JP7366002B2 (ja) | 2023-10-20 |
| JP7642707B2 (ja) | 2025-03-10 |
| JP2020530837A (ja) | 2020-10-29 |
| RU2020108634A3 (enExample) | 2021-11-30 |
| US20250017890A1 (en) | 2025-01-16 |
| KR20200045489A (ko) | 2020-05-04 |
| KR102643275B1 (ko) | 2024-03-04 |
| CN111094238B (zh) | 2023-06-09 |
| EP3661911A1 (en) | 2020-06-10 |
| SA520411187B1 (ar) | 2024-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020108634A (ru) | Аналоги карбамоилфенилаланинола и способы их применения | |
| JP2020530837A5 (enExample) | ||
| FI3509582T3 (fi) | (r)-2-amino-3-fenyylipropyylikarbamaatin solvaattimuoto | |
| JP2017503000A5 (enExample) | ||
| JP2015517574A5 (enExample) | ||
| RU2009149292A (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| JP2014515406A5 (enExample) | ||
| JP2016506935A5 (enExample) | ||
| RU2015133450A (ru) | Соединения имидазопиридина и их применение | |
| JP2016040288A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| RU2009115653A (ru) | Производные 5-замещенного хиназолинона, содержащие их композиции и способы их применения | |
| JP2016505586A5 (enExample) | ||
| JP2016522266A5 (enExample) | ||
| RU2017106172A (ru) | Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn) | |
| JP2016505637A5 (enExample) | ||
| JP2007508360A5 (enExample) | ||
| PE20140836A1 (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide | |
| JP2014505107A5 (enExample) | ||
| RU2013141559A (ru) | Способ ингибирования клеток опухоли гамартомы | |
| RU2018105614A (ru) | Производное 1,3,5-триазина и способ его применения | |
| RU2016134751A (ru) | Соединения | |
| JP2016506961A5 (enExample) | ||
| RU2015126015A (ru) | Новые улавливатели в лечении макулодистрофии | |
| JP2017502092A5 (enExample) |